TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01923675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spectacles with red-blocking tint
Description: Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.

Intervention type: OTHER
Group type: OTHER
Intervention: Spectacles with holographic diffuser and color neutral tint
Description: Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.

Intervention type: OTHER
Group type: OTHER
Intervention: Spectacles with holographic diffuser and red-blocking tint
Description: Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.

Intervention type: OTHER
Group type: OTHER
Intervention: Spectacles with color neutral tint
Description: Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.
Study: NCT03214679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accessible Care
Description: Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care entails referral to an on site HCV care coordinator (not provided by study)
Study: NCT04617795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod 5 Automated Insulin Delivery System
Description: The Omnipod 5 is a single hormone insulin delivery system intended for the management of diabetes in persons requiring insulin. Continuous subcutaneous insulin infusion may be delivered by user-defined settings (manual mode) or automatically adjusted in response to feedback from a continuous glucose monitor (CGM).~The Omnipod 5 can automatically increase insulin delivery based on sensor glucose values from the continuous glucose monitor (CGM) and can decrease or suspend delivery of insulin when the glucose value falls below or is predicted to fall below predefined threshold values.~The Omnipod 5 is designed to assist patients with diabetes in achieving glycemic targets set by their health care providers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod 5 Automated Insulin Delivery System
Description: The Omnipod 5 is a single hormone insulin delivery system intended for the management of diabetes in persons requiring insulin. Continuous subcutaneous insulin infusion may be delivered by user-defined settings (manual mode) or automatically adjusted in response to feedback from a continuous glucose monitor (CGM).~The Omnipod 5 can automatically increase insulin delivery based on sensor glucose values from the continuous glucose monitor (CGM) and can decrease or suspend delivery of insulin when the glucose value falls below or is predicted to fall below predefined threshold values.~The Omnipod 5 is designed to assist patients with diabetes in achieving glycemic targets set by their health care providers.
Study: NCT00920777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Individual Cognitive Behavior Therapy during 16 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Individual Cognitive Behavior Therapy during 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Waiting 16 weeks and receiving 8 weeks individual CBT after waiting period.
Study: NCT00181883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: 2.5 - 5.0mg/kg PO BID quetiapine
Study: NCT01736735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00302536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus
Study: NCT03885323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF utilizing powered toothbrush
Description: RF utilizing Powered toothbrush

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control placebo with no RF
Description: Placebo control, with no RF
Study: NCT04441788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION-827359
Description: ION-827359 administered by oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION-827359
Description: ION-827359 administered by oral inhalation
Study: NCT04218721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: InvolveMe
Description: An eHealth application that allows participants to report symptoms and needs prior to out-patient visits at the hospital. The application creates a summary that allows patients to prioritize what is important to talk with their health care providers about. Health care providers can use the summary to prepare the consultation.
Study: NCT00829699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: euinsulinemic euglycemic glucose clamp
Description: euinsulinemic euglycemic glucose clamp with lipid infusion 48 ml/hr for 4 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: euinsulinemic hyperglycemic glucose clamp
Description: euinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic glucose clamp
Description: Hyperinsulinemic euglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic hyperglycemic glucose clamp
Description: Hyperinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
Study: NCT00995722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
Study: NCT02945735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Modification
Description: Feedback according to participants' viewing patterns, in order to modify their attention.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Modification
Description: Feedback according to participants' viewing patterns, in order to modify their attention.
Study: NCT02052427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celution System
Description: ADRCs processed by the Celution System for reintroduction into the myocardium
Study: NCT03598894

Intervention type: OTHER
Intervention: Ambulatory blood pressure measurements
Description: Blood pressure will be assessed with ambulatory blood pressure measurements over the course of a day to discern day/night differences

Intervention type: OTHER
Intervention: Ambulatory blood pressure measurements
Description: Blood pressure will be assessed with ambulatory blood pressure measurements over the course of a day to discern day/night differences
Study: NCT02052427

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological solution made of Lactated Ringers solution and a small amount (\<1mL) of autologous blood
Study: NCT00640939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac sodium
Description: 15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
Study: NCT03604848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WHO-approved MDR-TB regimen
Description: Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGS-guided regimen: Regimen A
Description: Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGS-guided regimen: Regimen B
Description: Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGS-guided regimen: Regimen C
Description: Based on the drug susceptibility test results, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol.~The dose of linezolid, clofazimine or ethambutol as follows:~Linezolid: 600 mg daily, clofazamine: 33-50kg 50 mg daily, 51-70kg 100 daily, \>70kg 100 mg daily; ethambutol: 33-50kg 800 mg daily, 51-70kg 800 daily, \>70kg 1200 mg daily;
Study: NCT03957486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arterila cannulation on same arm
Description: arterila cannulation on same arm receiving continous hemoglobin monitoring

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: arterila cannulation on different arm
Description: arterila cannulation different arm receiving continous hemoglobin monitoring
Study: NCT02128659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHE Project
Description: Consists of five-sessions, starting on a Monday and ending Friday. Each day involves an approximately 2 hour session.
Study: NCT06478511

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic Immediate implant
Description: The teeth will be extracted gently using periotomes to preserve facial and lingual bone plates. All walls of the socket will be inspected and checked for the presence of fenestration or dehiscence defects in bone. The length and width of extracted roots will be measured to determine the length and diameter of implants placed. The osteotomy sites will be prepared and the drills will be used in proper sequence according to manufacturer's instructions, with maximum use of bone apical to the extraction sockets. The drills will extend 3 to 5 mm beyond the apex of the socket to ensure primary stability after placement, taking care of the anatomical boundaries. The implants will be placed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant combined with subepithelial connective tissue graft
Description: Connective tissue graft was harvested from palate using trap door technique utilizing a horizontal incision 3-4 mm away from the gingival margin with two vertical incisions on the either end of the first incision, the door is then undermined and opened using a sharp dissection, the underlying connective tissue is then harvested using a periosteal elevator, and the door was then sutured using 4 0 silk sutures Finally, the connective tissue graft was immediately placed into the recipient site after a tunneling procedure and sutured with 6-0 nonresorbable monofilament sutures.
Study: NCT02128659

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHE Project
Description: Consists of five-sessions, starting on a Monday and ending Friday. Each day involves an approximately 2 hour session.
Study: NCT04063735

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cordyceps Cicadae Mycelia
Description: Cordyceps Cicadae Mycelia supplement for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given to participants.
Study: NCT01968187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 992097

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06478511

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate dental implant placement using socket shield technique
Description: The crown of the involved tooth will be removed and the root will be then sectioned in a mesiodistal direction along its long axis as far apical as was possible using a long shank fissure bur. Preserving the facial root section unmanipulated and attached to the tooth socket. Periotomes will be then inserted between the palatal root removed gentelly.The remaining root section will be then reduced coronally to 1 mm above the alveolar crest.The tooth socket's palatal wall and apex will be then curetted to remove any tissue or infective remnants and the root section will be checked for immobility with a sharp probe. With the preparation steps complete, the tooth root hereafter will be known as the socket-shield. An osteotomy will be then sequentially prepared and internal conical connection implant was inserted palatal to the shield with the implant 2 mm below the facial crest.
Study: NCT02156323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMS
Description: Multiple doses of CMS over 2.5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMS
Description: Multiple doses of CMS over 2.5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7033877
Description: Multiple doses of RO7033877 over 2.5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7033877
Description: Multiple doses of RO7033877 over 2.5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7033877 + CMS
Description: Multiple doses of RO7033877 and CMS over 2.5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7033877 + CMS
Description: Multiple doses of RO7033877 and CMS over 2.5 days
Study: NCT03412877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Individual Patient TCR-Transduced PBL
Description: Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Individual Patient TCR-Transduced PBL
Description: Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA )
Description: Arm 2: Pembrolizumab 2 mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
Study: NCT00118989

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcuminoids
Description: Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Curcuminoids
Description: Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
Study: NCT03868189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroneuromyography with ultrasound
Description: Patients whose electroneuromyography examination will be performed using an ultrasound

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electroneuromyography without ultrasound
Description: Patients whose electroneuromyography examination will be performed without ultrasound (fake tracking)
Study: NCT03011177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin
Description: teneligliptin 20mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: linagliptin 5mg qd
Study: NCT00826059

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Sphenopalatine Ganglion (SPG) Stimulation
Description: SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Sphenopalatine Ganglion (SPG) Stimulation
Description: Sham SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
Study: NCT01116622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene (Targretin®)
Description: Level -I 200 mg/m2 Level I 300 mg/m2 Level II 300 mg/m2 Level III 400 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva™)
Description: Level -1 100mg Level I 100mg Level II 150mg Level III 150mg
Study: NCT03516162

Intervention type: OTHER
Intervention: There is no study-specific intervention
Description: There is no study-specific intervention
Study: NCT04587141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrosomial iron
Description: This is an oral iron formulation commercially available as an integrator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Gluconate
Description: This is a commercially available iron formulation for parenteral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: This is a commercially available iron formulation for parenteral administration
Study: NCT00638469

Intervention type: RADIATION
Group type: OTHER
Intervention: UVB-311nm
Description: UVB-311nm radiation given 3 times a week to one randomized body half

Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: no UV exposure
Study: NCT03476057

Intervention type: DIAGNOSTIC_TEST
Intervention: Device： NGS sequencing cfDNA
Description: NGS sequencing cfDNA and Tumor Burden
Study: NCT02030119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily feedback
Study: NCT00587691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tovaxin Autologous T Cell Vaccine
Description: Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.~Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.~Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tovaxin Autologous T Cell Vaccine
Description: Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.~Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.~Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tovaxin Autologous T Cell Vaccine
Description: Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.~Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.~Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods.